Analysis of Clinical Efficacy and Safety of Ustekinumab in Treatment of Inflammatory Bowel Disease

Author: Sa FANG ¹ ; Shuang HAN ¹ ; Sa FANG ² ; Kaichun WU ² ; Yongquan SHI ² ; Yulong WANG ² ; Xiaofei LI ² ; Jie LIANG ² ; Min CHEN ²
Author Information

1. Department of Gastroenterology, Honghui Hospital, Xi’an Jiaotong University
2. Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Air Force Medical University
Publication Type:Journal Article
Keywords: Colitis, Ulcerative; Crohn Disease; Inflammatory Bowel Disease; Therapy; Ustekinumab
From: Chinese Journal of Gastroenterology 2022;27(12):711-716
CountryChina
Language:Chinese
Abstract: Background: The efficacy of ustekinumab (UST) in the treatment of patients with inflammatory bowel disease (IBD) has been affirmed abroad, but its efficacy and safety have not been reported in China due to its short term of use. Aims: To analyze the clinical efficacy and safety of UST in the treatment of IBD. Methods: The clinical data of IBD patients treated with UST from November 2020 to June 2022 in the First Affiliated Hospital of Air Force Medical University were analyzed retrospectively. Results: A total of 46 patients with IBD treated with UST were enrolled, including 41 patients with Crohn’s disease (CD) and 5 patients with ulcerative colitis (UC). At the 8